BCRX vs HAE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BCRX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCRX and HAE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCRX and HAE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Its lead product is ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved to prevent HAE attacks, which competes against injectable and infused prophylaxis therapies. The company also markets RAPIVAB (peramivir) for influenza and, through its January 2026 acquisition of Astria Therapeutics, added navenibart (formerly STAR-0215), a long-acting injectable antibody in Phase 3 for HAE prophylaxis, plus an early-stage ocular program (avoralstat).

Full BCRX guide

Haemonetics Corporation, based in Boston and listed on the NYSE, has sold blood-handling technology since 1971. Its largest business is plasma: the NexSys PCS apheresis machines, and the far more profitable single-use disposable kits that run on them, sit in the collection centers operated by companies like Grifols, Takeda's BioLife and Octapharma, which turn donated plasma into immunoglobulin and other plasma-derived therapies. A second business, grouped under the hospital umbrella, splits into Interventional Technologies (the VASCADE and VASCADE MVP vascular closure devices used after catheter procedures, plus the OpSens optical pressure sensing line and the Attune Medical esophageal cooling device) and Blood Management Technologies (TEG viscoelastic hemostasis analyzers, Cell Saver autotransfusion systems, and blood-tracking software). A third and shrinking business supplies whole-blood and apheresis collection to blood banks.

Full HAE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BCRX drivers: ORLADEYO revenue growth and operating leverage; Navenibart and the Astria pipeline bet.
• HAE drivers: Plasma without the CSL overhang; Yield software as a razor-blade lever.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard. For HAE, customer concentration is the structural risk: plasma collection in the United States is consolidated into a handful of buyers, and the CSL departure showed how much revenue a single non-renewal can remove.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BCRX if you believe its drivers more; HAE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCRX and HAE guides.

BCRX. BioCryst trades on the strength and durability of its ORLADEYO franchise rather than on GAAP earnings, since 2026 results were dominated by a roughly $698 million one-time non-cash acquired-IPR&D charge from the Astria deal that produced a large GAAP operating loss. On a non-GAAP basis the company reported operating profit and reaffirmed full-year revenue guidance. Because so much value sits in a single growing product plus a late-stage pipeline candidate, the market cap reflects expectations for peak ORLADEYO sales and navenibart success as much as trailing figures.

HAE. A little over three times sales is an unremarkable multiple for a medical-device company with high-margin recurring disposables, and it reflects several years in which reported growth was held down by the CSL transition rather than by demand. The August 2026 print was the first quarter in a while where reported and organic growth were the same number, which is what happens when the lost contract finally leaves the comparison. What the multiple is really pricing is whether mid single-digit organic growth is the ceiling or the floor.

Headline figures (approximate, JUNE 2026): BCRX shows revenue (ttm) ~$630M, q1 2026 total revenue ~$156M, q1 2026 orladeyo revenue ~$148M (up ~11% YoY), 2026 orladeyo guidance ~$625M to $645M; HAE shows market cap ~$4.13B, revenue (ttm) ~$1.35B, share price ~$90.80, price / ttm sales ~3.1x.

BCRX and HAE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BCRX and HAE exposure against your real portfolio. It is not an investment adviser.